Skip to content
naulon
Not checkedNot checked for notices yet.

Experts Opinion on the Use of Biologic Agents in Psoriatic Patients during COVID-19 Outbreak#

Gang Wang, Heng Gu, Min Zheng and 6 more

International Journal of Dermatology and Venerology · 2020

doi:10.1097/jd9.0000000000000097 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Abstract. The coronavirus disease 2019 (COVID-19) outbreak affects the use of biologics for psoriatic patients, in the way that the consequential immunosuppression potentially alters a patient's susceptibility to the virus or deteriorate the condition if the patient is infected or even change the prognosis of infection. Therefore, authors reviewed currently available recommendations from international psoriasis academic organizations and specialists, and summarized them with the specific situation in China. We are trying to provide guidance to the use of biologics for psoriatic patients in the following contexts: patients on biologic therapy, patients being considered for biologic therapy initiation, patients with low-risk or high-risk of SARS-CoV-2 coronavirus infection, patients tested negative or positive for the nucleic acid testing of virus.

Abstract licence: CC BY-NC-ND

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.